InMed Pharmaceuticals Inc.
For the period ended Jun 30, 2025. Filed Sep 23, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Sep 23, 2025
INM$15.56+17.8%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
For the years ended June 30, 2025 and 2024
| 2025 · 2024 | ||||
|---|---|---|---|---|
| $ · $ | ||||
| Cash provided by (used in): | ||||
| Operating Activities | ||||
| Net loss | (8,162,133) | (7,675,550) | ||
| Items not requiring cash: | ||||
| Amortization and depreciation | 212,839 | 219,600 | ||
| Share-based compensation | 119,307 | 137,714 | ||
| Amortization of right-of-use assets | 321,885 | 384,918 | ||
| Interest income received on short-term investments | (34) | (1,250) | ||
| Unrealized foreign exchange loss | 75,928 | 12,262 | ||
| Inventory write-down | - | 305,812 | ||
| Credit losses | 2,424 | - | ||
| Changes in operating assets and liabilities: | ||||
| Inventories | 283,151 | 66,220 | ||
| Prepaids and other currents assets | 173,980 | 20,284 | ||
| Other non-current assets | - | 4,908 | ||
| Accounts receivable | (114,690) | (92,439) | ||
| Accounts payable and accrued liabilities | (249,728) | 45,282 | ||
| Deferred rent | - | (16,171) | ||
| Lease obligations | (429,880) | (397,422) | ||
| Total cash used in operating activities | (7,766,951) | (6,985,832) | ||
| Investing Activities | ||||
| Purchase of property and equipment | - | (9,293) | ||
| Sale of short-term investments | 42,270 | 42,082 | ||
| Purchase of short-term investments | (42,270) | (42,082) | ||
| Total cash used in investing activities | - | (9,293) | ||
| Financing Activities | ||||
| Proceeds from the exercise of pre-funded warrants | - | 175 | ||
| Proceeds from the private placement | 8,130,299 | 5,216,194 | ||
| Proceeds from the sale of pre-funded warrants | 5,024,891 | - | ||
| Share issuance costs | (883,978) | (562,151) | ||
| Total cash provided by financing activities | 12,271,212 | 4,654,218 | ||
| Increase (decrease) in cash and cash equivalents during the year | 4,504,261 | (2,340,907) | ||
| Cash and cash equivalents beginning of the year | 6,571,610 | 8,912,517 | ||
| Cash and cash equivalents end of the year | 11,075,871 | 6,571,610 | ||
| SUPPLEMENTARY CASH FLOW INFORMATION: | ||||
| Cash Paid During the Year for: | ||||
| Income taxes | $ | - | $7,100 | |
| Interest | $ | - | $ | - |
| SUPPLEMENTARY DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES: | ||||
| Preferred investment options to its placement agent | $281,810 | $325,699 | ||
| Fair value of warrant modification recorded as equity issuance costs | $116,482 | $3,508,749 | ||
| Recognition of Right-of-use asset and corresponding operating lease | $187,223 | $968,376 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.